1.47
-0.68%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Racura Oncology
Its shares trade on ASX under the ticker RAC.AX. It has been listed since 13 July 2016. In the fiscal year to 30 June 2025, it reported revenue of A$6.0m and a net loss of A$4.8m. At that date it held total assets of A$17.5m and shareholders' equity of A$16.0m.
Race Oncology Ltd. is a precision oncology company, which engages in the discovery and development of the phase 2/3 cancer drug called Zantrene. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The firm is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The firm also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jul 2016
- Website
- raceoncology.com ↗
Leadership
Pay as last reported
- Dr. Peter SmithExecutive Chairman of the Board, since 2023A$327,718
- Dr. Daniel TillettChief Executive Officer, Managing Director, Executive Director, since 2019A$1.1m
- Mr. Brendan BrownChief Financial Officer
- Dr. Sophia MoscovisVice President - Operations and Strategy
- Dr. Simon FisherVice President - Clinical
- Prof. Michael KelsoVice President - Research
- Dr. Marinella MessinaVice President - Clinical Development
- Dr. Jose IglesiasChief Medical Officer
- Mr. Peter WebseCompany Secretary
- Dr. Megan BaldwinNon-Executive Independent Director
- Dr. Serge ScrofaniNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on precision oncology with a phase 2/3 cancer drug called Zantrene.
- Zantrene targets FTO-driven cancers including melanoma and kidney cancer.
- The company has clinical data for Zantrene in multiple cancer types including AML and breast cancer.
Weaknesses
- The company's drug Zantrene is still in phase 2/3 development.
- The company has limited clinical data for Zantrene in some cancer types.
- The company is a biotechnology firm with no commercialized products.
Opportunities
- Zantrene has potential for use in multiple cancer types including melanoma and kidney cancer.
- The company could expand its clinical data for Zantrene in additional cancer types.
- Zantrene's cardio-protective properties may differentiate it from other chemotherapeutics.
Threats
- Zantrene's development is still in phase 2/3, which carries high risk of failure.
- The biotechnology sector is highly competitive with many companies developing similar drugs.
- The company's financial stability is uncertain due to lack of commercialized products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.